Atea Pharmaceuticals Presents Initail Phase 2 Results for Bemnifosbuvir And Ruzasvir Mix In Treating Hepatitis C At The 2024 EASL Congress
Benzinga Newsdesk 2 years ago
News
97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study EASL Presentations Continue to Support Best-in-Class Potential with High Antiviral
- 97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study
- EASL Presentations Continue to Support Best-in-Class Potential with High Antiviral Potency, Short Treatment Duration, Low Risk of Drug Interaction and High Barrier to Resistance